GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care.  At | Cancer ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

When Carter was diagnosed with metastatic melanoma, he told the country he'd be trying a new cutting-edge cancer treatment - immunotherapy.

Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Viracta Therapeutics announced the closure of a phase II trial of its combination therapy of the histone deacetylase ...